Mereo BioPharma Group plc

NasdaqCM:MREO Stock Report

Market Cap: US$435.5m

Mereo BioPharma Group Management

Management criteria checks 4/4

Mereo BioPharma Group's CEO is Denise Scots-Knight, appointed in Jul 2015, has a tenure of 8.83 years. total yearly compensation is $2.22M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.86% of the company’s shares, worth $8.11M. The average tenure of the management team and the board of directors is 6.2 years and 3.1 years respectively.

Key information

Denise Scots-Knight

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage25.5%
CEO tenure8.8yrs
CEO ownership1.9%
Management average tenure6.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Nov 25
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Oct 17

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Oct 03

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

CEO Compensation Analysis

How has Denise Scots-Knight's remuneration changed compared to Mereo BioPharma Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$565k

-US$29m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$2mUS$507k

-US$42m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$2mUS$539k

US$17m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$1mUS$545k

-US$224m

Sep 30 2020n/an/a

-US$198m

Jun 30 2020n/an/a

-US$177m

Mar 31 2020n/an/a

-US$111m

Dec 31 2019US$2mUS$518k

-US$46m

Sep 30 2019n/an/a

-US$41m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$957kUS$484k

-US$41m

Sep 30 2018n/an/a

-US$42m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$50m

Dec 31 2017US$907kUS$493k

-US$52m

Compensation vs Market: Denise's total compensation ($USD2.22M) is about average for companies of similar size in the US market ($USD2.40M).

Compensation vs Earnings: Denise's compensation has been consistent with company performance over the past year.

CEO

Denise Scots-Knight (64 yo)

8.8yrs

Tenure

US$2,219,323

Compensation

Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...

Leadership Team

NamePositionTenureCompensationOwnership
Denise Scots-Knight
Co-Founder8.8yrsUS$2.22m1.86%
$ 8.1m
Charles Sermon
Co-Founder9yrsUS$1.09m0.59%
$ 2.6m
Christine Fox
Chief Financial Officer3.3yrsUS$1.00m0.28%
$ 1.2m
John Richard
Co-Founder & Chief Business Officer9.3yrsno data0.055%
$ 240.2k
John Lewicki
Chief Scientific Officer3.8yrsno data0.013%
$ 56.6k
Jackie Parkin
Senior VP & Therapeutic Headno datano datano data
Alexandra Hughes-Wilson
Chief of Patient Access & Commercial Planning6.2yrsno data0.0055%
$ 23.8k
Suba Krishnan
Senior Vice President of Clinical Development3.4yrsno datano data
Bo Kara
Senior VP and Head of Pharmaceutical Development & CMCno datano datano data

6.2yrs

Average Tenure

61yo

Average Age

Experienced Management: MREO's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Denise Scots-Knight
Co-Founder9.2yrsUS$2.22m1.86%
$ 8.1m
Michael Wyzga
Independent Non-Executive Chairman of The Board5.1yrsUS$156.80k0.12%
$ 531.8k
Deepika Pakianathan
Independent Non-Executive Director5.1yrsUS$113.76k0.12%
$ 531.8k
Anders Ekblom
Independent Non-Executive Director8.8yrsUS$121.31k0.18%
$ 784.3k
Marc Yoskowitz
Independent Director1.5yrsUS$94.49k0.051%
$ 222.9k
Annalisa Lisa Jenkins
Independent Director1.5yrsUS$100.96k0.051%
$ 222.9k
Jeremy Bender
Independent Non Executive Director3.6yrsUS$105.08k0.12%
$ 531.8k
Daniel Shames
Independent Director1.5yrsUS$97.75k0.051%
$ 222.9k
Pierre Jacquet
Independent Director2.7yrsUS$102.18k0.11%
$ 469.3k
Justin Roberts
Independent Director1.5yrsno datano data

3.1yrs

Average Tenure

58yo

Average Age

Experienced Board: MREO's board of directors are considered experienced (3.1 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.